Kiniksa Pharmaceuticals International, plc (KNSA) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary and Q&A indicate strong financial performance, positive feedback from patients and physicians, and increased prescriber numbers for ARCALYST. The raised sales guidance for 2025 and strategic marketing efforts further bolster the outlook. Despite some unclear management responses, the overall sentiment is positive, with a focus on growth and market penetration. Given the company's market cap, this is likely to result in a stock price increase of 2% to 8% over the next two weeks.
Key Financial Performance
ARCALYST revenue $180.9 million in Q3 2025, a 61% year-over-year growth. This growth was driven by the adoption of IL-1 alpha and beta inhibition for recurrent pericarditis, leading to significant gains in active commercial patients and duration of therapy.
Operating expenses $156.8 million in Q3 2025, a 29% year-over-year increase. The increase was primarily due to collaboration expenses driven by strong ARCALYST collaboration profit growth.
Net income $18.4 million in Q3 2025, compared to a net loss of $12.7 million in Q3 2024. This improvement was due to strong revenue growth against more moderate operating expense growth.
ARCALYST collaboration profit $126.6 million in Q3 2025, a 118% year-over-year growth. This was due to profit split eligible COGS and commercial and marketing costs holding steady against higher sales.
Cash balance $352.1 million at the end of Q3 2025, an increase of approximately $44 million from the previous quarter. This reflects the company's ability to remain cash flow positive on an annual basis.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
ARCALYST revenue growth: ARCALYST revenue grew to $180.9 million in Q3 2025, a $24 million increase from the previous quarter and $69 million higher than Q3 2024. Full-year net sales guidance was raised to $670-$675 million from $625-$640 million.
KPL-387 development: KPL-387 received FDA Orphan Drug Designation for recurrent pericarditis. Phase II/III trial data is expected in the second half of 2026. The drug aims to expand market penetration with a monthly subcutaneous dose.
Market penetration for ARCALYST: ARCALYST is only 15% penetrated into the multiple recurrence patient population, with 20% of prescriptions written for patients after their first recurrence. The market is expected to grow with increased adoption of IL-1 alpha and beta inhibition.
KPL-387 market potential: Surveyed patients and healthcare professionals show strong preference for KPL-387's target profile, with 75% of patients and 90% of professionals likely to adopt it. The drug is expected to expand the IL-1 alpha and beta inhibition market.
Operational efficiency: ARCALYST collaboration profit grew 118% year-over-year to $126.6 million in Q3 2025. Operating expenses grew 29% year-over-year, but revenue growth outpaced expense growth, leading to a net income of $18.4 million compared to a $12.7 million loss in Q3 2024.
Patient support and education: Kiniksa has enhanced patient support through Kiniksa OneConnect and improved physician targeting using AI and digital marketing, contributing to increased patient satisfaction and treatment duration.
Strategic focus on IL-1 inhibition: Kiniksa is focused on becoming the market leader in recurrent pericarditis treatment through its IL-1 inhibition franchise, including ARCALYST and KPL-387. The company is advancing education and adoption of IL-1 alpha and beta inhibition as the standard of care.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Market Penetration: Despite growth, ARCALYST has only achieved 15% penetration into the multiple recurrence patient population, indicating challenges in fully capturing the market.
Regulatory and Development Risks: The success of KPL-387 is contingent on the outcome of ongoing Phase II/III trials, with data expected in 2026. Any delays or negative results could impact future growth.
Competition: The introduction of KPL-387 faces competitive pressures, as healthcare professionals and patients may compare it to existing and investigational therapies.
Economic and Industry Dynamics: Year-end industry dynamics and historical fourth-quarter performance trends could impact revenue projections.
Operational Costs: Operating expenses grew 29% year-over-year, driven by collaboration expenses, which could pressure profitability if revenue growth slows.
Supply Chain and Manufacturing: The ability to maintain high payer approval rates and patient support through Kiniksa OneConnect is critical, and any disruptions could affect patient access and satisfaction.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance: The company has raised its full-year net sales guidance for ARCALYST to between $670 million and $675 million, up from the previous guidance of $625 million to $640 million. This reflects robust revenue growth and accounts for typical year-end industry dynamics.
Market Penetration and Growth: ARCALYST is currently only 15% penetrated into the multiple recurrence patient population, indicating significant room for growth. The company expects continued revenue growth as ARCALYST is increasingly utilized earlier in the disease course.
KPL-387 Development: The company remains on track to report data from the Phase II dose focusing portion of the Phase II/III trial for KPL-387 in the second half of 2026. KPL-387 has received Orphan Drug Designation from the FDA for the treatment of pericarditis, including recurrent pericarditis.
Market Expansion with KPL-387: KPL-387 is expected to expand the recurrent pericarditis market by offering a convenient monthly subcutaneous dose in an auto-injector. Surveys indicate strong preference among patients and healthcare professionals for this target profile, with 75% of patients and 90% of healthcare professionals favoring it over current therapies.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What feedback are you receiving from patients and physicians regarding the longer duration of ARCALYST usage?
A:Patients and physicians have provided positive feedback on the longer duration of ARCALYST usage. Academic literature highlights the necessity of treating the disease for its full duration to minimize recurrences. Data presented at the European Society of Cardiology meetings showed a 99.5% reduction in event rates with continued treatment. Healthcare professionals appreciate the high access rates and ease of therapy initiation, while patients report high satisfaction and good tolerance of the drug.
Q:How have the updated ACC guidelines been incorporated into your marketing efforts?
A:The updated ACC guidelines, released in August, affirm the use of IL-1 pathway inhibition as a second-line treatment after NSAIDs and colchicine, positioning ARCALYST as a steroid-sparing agent. The guidelines have been incorporated into promotional materials, reinforcing the messaging that ARCALYST is a modern, targeted immunomodulation therapy addressing the key drivers of the disease.
Q:What is the strategy for addressing the first recurrence population and driving further penetration?
A:The label for ARCALYST is agnostic to the number of flares, allowing its use in the first recurrence of recurrent pericarditis. While initial adoption was higher in the 2+ recurrence group, representing 14,000 patients annually, 20% of prescriptions are now for the first recurrence group. Physicians are increasingly confident in prescribing ARCALYST earlier, aiming to prevent additional flares. The company sees significant growth potential, with only 15% penetration in the 2+ recurrence group so far.
Q:Can you discuss the gross-to-net dynamics for ARCALYST this quarter?
A:The gross-to-net percentage for ARCALYST was 8.9% year-to-date, down from 9.5% in the second quarter. This aligns with historical patterns, where the percentage is highest in the first quarter due to benefit plan resets and co-pay support, lower in the second and third quarters, and slightly higher in the fourth quarter.
Q:What factors will influence the Phase III dose decision for KPL-387?
A:The Phase II study for KPL-387 is a dose-focusing study, anchored on a 300-milligram subcutaneous monthly dose. Modeling suggests this dose provides sufficient coverage. The study will evaluate whether higher or lower doses affect efficacy, affirming the 300-milligram dose for Phase III.
Q:What drove the increase in the number of ARCALYST prescribers this quarter, and what is the plan to sustain this growth?
A:The quarter saw the highest increase in new prescribers since launch, with over 350 new prescribers, bringing the total to 3,825. Factors include increased confidence, awareness, and validation from the ACC guidelines. The company uses targeted sales efforts, AI, digital marketing, and innovative approaches to identify and reach potential prescribers and patients. Efforts also focus on supporting prescribers to identify additional patients.
Q:Why do some patients not restart ARCALYST after stopping, and what is the average duration of therapy?
A:The average initial treatment duration is 17.5 months, with 45% of patients restarting therapy after stopping. Patients who do not restart may have resolved symptoms or no longer require treatment. The average total duration of therapy, including restarts, is now 32 months.
Q:How does the company view the competitive landscape with upcoming Phase II data from a competitor?
A:The company acknowledges that inflammasome inhibitors may show short-term efficacy in reducing C-reactive protein levels. However, ARCALYST targets both IL-1 alpha and beta, addressing the root cause of recurrent pericarditis. Long-term data from the RHAPSODY study demonstrated a 99.5% reduction in events, setting a high bar for effective therapy.
Q:What is the purpose of the transition arm in the KPL-387 study?
A:The transition arm aims to provide data on how to move patients from other therapies (e.g., NSAIDs, colchicine, corticosteroids, IL-1 inhibitors) to KPL-387 monotherapy. It is designed to inform regulatory authorities and clinicians on effective dosing paradigms for transitioning patients.
Q:Review of Unclear Management Responses
A:Management did not provide clear answers to the following: 1) Why some patients do not restart ARCALYST after stopping, as the company does not collect data on this. 2) Specific details on the collaboration expense and tax rate increases, as no one-off factors were identified. 3) The exact proportion of recurrent pericarditis patients seen by the 3,800 prescribers, as this was not addressed directly.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI marketing
Chairman date
Chief Corporate
Corporate Commercial
Designation treatment
Drug Designation
FDA KPL
III development
IL alpha
IL inhibition
Phase II
adoption IL
beta inhibition
care patient
care professional
community
cytokine
development program
dose
hand side
health care
income
inhibition franchise
number patient
patient duration
patient treatment
penetration market
portion Phase
profile
progress
support
today program
treatment pericarditis
utilization
KNSA Transcript
Kiniksa Pharmaceuticals International, plc (KNSA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Neutral6-10
Kiniksa Pharmaceuticals International, plc (KNSA) Q1 2026 Earnings Call Transcript
Unknown4-28
The earnings call summary showed mixed signals. Financial performance was positive with a 15% revenue increase and a 43% rise in net income. However, increased R&D expenses and cash decline indicate financial strain. Risks in clinical trials and ARCALYST's commercial execution add uncertainty. The market cap suggests moderate sensitivity to news, and without strong positive catalysts or partnership announcements, the overall sentiment remains neutral.
Kiniksa Pharmaceuticals International, plc (KNSA) Q4 2025 Earnings Call Transcript
Positive2-24
The company demonstrated strong financial performance with significant revenue and net income growth, improved guidance, and robust cash generation. ARCALYST's market penetration shows potential for further growth, and KPL-387 offers promising expansion opportunities. Despite competitive pressures and vague management responses on certain aspects, the overall sentiment remains positive due to raised guidance, strong product adoption, and strategic market positioning. Given the market cap, the expected stock price movement is positive (2% to 8%).
Kiniksa Pharmaceuticals International, plc (KNSA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-12
KNSA Slides
KNSA Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
